MannKind Corp $ 1.56 0.05 (3.31%)
Warning! GuruFocus has detected 2 Severe warning signs with MNKD. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for MNKD (MannKindrp) from 2004 to Feb 23 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. MannKind stock (MNKD) PE ratio as of Feb 23 2020 is 0. More Details
MannKind PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
MannKind PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:OSMT XKRX:228760 NAS:REPH NAS:ETNB XKRX:263050 NAS:HARP XTER:FYB NAS:PSNL NAS:LXRX NAS:PDLI NAS:KIN OSL:HBC AMEX:PFNX NAS:CUE NAS:ANAB NAS:GRTS NYSE:RFL NAS:UROV TSE:7774 LSE:SLN
Address 30930 Russell Ranch Road, Suite 300, Westlake Village, CA, USA, 91362
MannKind Corp is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of therapeutic products and solutions for the patients with the diseases such as diabetes. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, Oral inhalers and others. The company has following products in the pipeline: Epinephrine technosphere, Treprostinil technosphere, and Palonosetron technosphere.